Characterization of bevacizumab dose response relationship in U87 brain tumors using magnetic resonance imaging measures of enhancing tumor volume and relative cerebral blood volume. J Neurooncol 2011 Nov;105(2):233-9
Date
05/03/2011Pubmed ID
21533524Pubmed Central ID
PMC4323180DOI
10.1007/s11060-011-0591-8Scopus ID
2-s2.0-82955233738 (requires institutional sign-in at Scopus site) 17 CitationsAbstract
Despite the early promising results with the anti-angiogenic agent, bevacizumab, to prolong time to progression in patients with brain tumors, the optimal dose and drug combinations have not yet been defined. The purpose of this study was to characterize the bevacizumab dose-response relationship for brain tumors by measuring the contrast-agent enhanced tumor volumes and relative cerebral blood volume (rCBV) using dynamic susceptibility contrast (DSC) imaging. The studies, performed in the U87 brain tumor model using doses of bevacizumab ranging from 0 to 10 mg/kg, demonstrate that tumor growth and vascularity are inhibited at all doses used, compared to untreated controls. However, only the maximum dose showed a statistically significant difference in growth rate. Conversely tumor vascularity, as measured with rCBV, was inhibited equally well for all doses used with no clear indication that higher doses are more effective.
Author List
Pechman KR, Donohoe DL, Bedekar DP, Kurpad SN, Hoffmann RG, Schmainda KMAuthors
Shekar N. Kurpad MD, PhD Chair, Director, Professor in the Neurosurgery department at Medical College of WisconsinKathleen M. Schmainda PhD Professor in the Biophysics department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Angiogenesis InhibitorsAnimals
Antibodies, Monoclonal, Humanized
Bevacizumab
Blood Volume
Brain Neoplasms
Contrast Media
Dose-Response Relationship, Drug
Gadolinium DTPA
Glioblastoma
Humans
Magnetic Resonance Imaging
Male
Rats
Tumor Burden
Tumor Cells, Cultured
